Retinopathy of prematurity

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
3 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
S Ophthalmology/ENT (ATC S) 2
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Receptor fusion protein 1 substance
Phase III: 3 Phase II: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

3 trials
  • Bayer AG Commercial
    AFLIBERCEPT
    2023-504207-89-00 10 countries 2020 n=39
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    AFLIBERCEPT
    2024-513231-24-00 2 countries 2022 n=7
    Ended
  • Universitaetsklinikum Tuebingen AöR Academic
    IMP not specified
    2024-511335-10-01 1 country 2018 n=865
    Ended

Phase II

1 trial
  • Universitaetsklinikum Tuebingen AöR Academic
    IMP not specified
    2024-511338-10-01 1 country 2024 n=100
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Universitaetsklinikum Tuebingen AöR Academic 2 Phase II, Phase III 1
Bayer AG Commercial 1 Phase III 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase III 0
New trials by year
2020
1
2022
1
2024
1
← All indication landscapes